Navigation Links
Kristalose(R) Offers Prescription Alternative to MiraLAX(R) and Other PEG 3350 Products
Date:2/26/2008

Unique, crystalline laxative designed to enhance patient acceptance and

compliance

NASHVILLE, Tenn., Feb. 26 /PRNewswire/ -- Kristalose(R), a prescription laxative product that treats acute and chronic constipation, may be an effective option for physicians and pharmacists looking for a prescription alternative to MiraLAX(R) and generic PEG 3350 products. Marketed in the U.S. by Cumberland Pharmaceuticals, Kristalose(R) is now the only prescription- strength laxative available in a convenient powder packet.

(Photo: http://www.newscom.com/cgi-bin/prnh/20080226/CLTU122 )

Previously available by prescription, MiraLAX(R) (polyethylene glycol 3350 or PEG 3350) became an over-the-counter (OTC) treatment for occasional constipation in early 2007. Due to U.S. Food and Drug Administration policy which does not allow the same formulation of a product to be marketed simultaneously as both a prescription and OTC drug, generic PEG 3350 products are now also becoming unavailable by prescription.(1) These generic products will not be available on the OTC market for at least three years following the MiraLAX(R) introduction due to marketing exclusivity granted by the FDA.

Physicians wrote more than 9 million prescriptions for MiraLAX(R) and generic PEG 3350 products in 2006 for treatment of constipation. As the PEG 3350 products are becoming unavailable by prescription, Cumberland believes Kristalose(R) offers a safe, effective alternative for physicians looking to retain prescriptive control for their patients.

Kristalose(R) (lactulose) for Oral Solution is a proprietary prescription laxative and the brand name for a unique crystalline form of lactulose that treats acute and chronic constipation. Available in pre-dosed packets, the drug dissolves quickly in four ounces of water, offering patients a virtually tasteless and grit-free alternative to other liquid lactulose treatments. There are no age limitations or length of use restrictions for Kristalose(R), and it is the only osmotic prescription laxative still sampled to physicians.

"Kristalose(R) has a long history of providing safe and effective relief to sufferers of acute and chronic constipation with few side effects," said A.J. Kazimi, CEO of Cumberland Pharmaceuticals. "We look forward to communicating the unique features of this drug to the medical community and ultimately to patients who may benefit from it."

Cumberland Pharmaceuticals Inc. is a Tennessee-based specialty pharmaceutical company that develops and markets niche pharmaceutical products for specific physician segments including critical care, emergency medicine and gastroenterology. Cumberland is dedicated to providing high-quality products which fill unmet medical needs. For more information, please visit the Cumberland Pharmaceuticals website at http://www.cumberlandpharma.com or http://www.kristalose.com.

To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and actual results or events may differ from Cumberland's expectations. Results may differ depending upon, among other things, the impact of actions by regulatory authorities on the marketing and distribution of products that compete with Kristalose(R). These statements speak only as of the date of this press release, and Cumberland undertakes no obligation to update or revise the statements.

Kristalose(R) is indicated for the treatment of acute and chronic constipation. It is a unique, proprietary, crystalline form of lactulose, with no restrictions on length of therapy or patient age. Initial dosing may produce flatulence and intestinal cramps, which are usually transient. Excessive dosage can lead to diarrhea with potential complications such as loss of fluids, hypokalemia and hypernatremia. Nausea and vomiting have been reported. Use with caution in diabetics. Kristalose(R) is contraindicated in patients who require a low-galactose diet. Elderly, debilitated patients who receive lactulose for more than six months should have serum electrolytes (potassium, chloride, carbon dioxide) measured periodically.

References

(1) Food and Drug Administration 21 CFR Part 310. Drug Approvals:

circumstances under which an active ingredient may be simultaneously

marketed in both a prescription product and an over-the-counter drug

product. Federal Register. Sept. 2005; 70(169) 52050-51. While the

FDA's interpretation does not have the force of law and is subject to

change at any time, it is the current interpretation of the FDA upon

which Cumberland believes it can rely.


'/>"/>
SOURCE Cumberland Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Health care incentive model offers collaborative approach
2. Eye-staining technique offers early detection for dry eye syndrome
3. Governor Rendell Offers adultBasic Coverage to 35,000 Uninsured Pennsylvanians
4. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
5. Psoriasis Cure Now offers Back to School Resources for Parents of Children with Psoriasis
6. ADDAS Awareness Campaign Offers Resources and Education to Adults Living with AD/HD and Professionals Working With Them
7. Regence Offers InterM to Fill Gap for the Uninsured
8. National Non-Profit Organization Offers Free Mental Health Services to Military and Military Families
9. Blue Cross Blue Shield of Michigan Offers New Approach to Customer Group Wellness
10. ProAssurance Group Offers Coverage for Community Based Hospitals in Michigan
11. Super Jake Foundation Offers Hope for Pediatric Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... Atlanta, GA (PRWEB) , ... December 07, 2016 , ... ... en route to respond to an emergency medical call when he lost control of ... injuries. After being extricated from his vehicle, he was transported to Atlanta Medical Center, ...
(Date:12/7/2016)... ... , ... Castle Dermatology Institute is now offering liquid facelifts with Sculptra ... to the face. Dr. Peyman Ghasri and Dr. Pedram Ghasri, San Fernando Valley ... rejuvenate and renew the facial appearance. , Sculptra is a highly effective injectable ...
(Date:12/7/2016)... ... 07, 2016 , ... Levels of a protein in the blood associated with ... online in the journal Radiology. , Heart disease and brain disease exact a major ... rapidly aging population. Damage to both organs often occurs at a subclinical stage, or ...
(Date:12/7/2016)... ... ... it came time to blow out his candles on his 14th birthday, Estefano Reano had ... team at Joe DiMaggio Children’s Hospital surprised his family with a phone call that ... , “He was playing at home, when we got the phone call telling us ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... from offices located in South Lyon, Dewitt, Williamston, East Lansing, Ann Arbor, and ... who needs treatment for a brain tumor. , Jason Bauer and his family ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... MOINES, Iowa , Dec. 8, 2016 /PRNewswire/ ... a pharmaceutical company advancing technologies designed to address ... appointment of Chitra Edwin , Ph.D., RAC, ... Compliance. Dr. Edwin will provide leadership for all ... for regulatory approvals, preparation of regulatory submissions, serving ...
(Date:12/7/2016)... 7, 2016 KEY FINDINGS ... such as reducing loss of blood during surgeries, ... arrests, rapid recovery after surgeries, and decreasing risks ... segmented into convective warming system, surface warming systems, ... reduce the stay at hospitals thus, lowering the ...
(Date:12/7/2016)... , Dec 7, 2016 Research and Markets ... and End User - Global Forecast to 2021" report to their ... , , ... 2.12 Billion by 2021, growing at a CAGR of 7.3% during the ... the growing prevalence of cancer and rapidly increasing geriatric population across the ...
Breaking Medicine Technology: